TY  - JOUR
A1  - Ovseiko, Pavel V.
A1  - Greenhalgh, Trisha
A1  - Adam, Paula
A1  - Grant, Jonathan
A1  - Hinrichs-Krapels, Saba
A1  - Graham, Kathryn E.
A1  - Valentine, Pamela A.
A1  - Sued, Omar
A1  - Boukhris, Omar F.
A1  - Al Olaqi, Nada M.
A1  - Al Rahbi, Idrees S.
A1  - Dowd, Anne-Maree
A1  - Bice, Sara
A1  - Heiden, Tamika L.
A1  - Fischer, Michael D.
A1  - Dopson, Sue
A1  - Norton, Robyn
A1  - Pollitt, Alexandra
A1  - Wooding, Steven
A1  - Balling, Gert V.
A1  - Jakobsen, Ulla
A1  - Kuhlmann, Ellen
A1  - Klinge, Ineke
A1  - Pololi, Linda H.
A1  - Jagsi, Reshma
A1  - Lawton Smith, Helen
A1  - Etzkowitz, Henry
A1  - Nielsen, Mathias W.
A1  - Carrion, Carme
A1  - Solans‐Domènech, Maite
A1  - Vizcaino, Esther
A1  - Naing, Lin
A1  - Cheok, Quentin H. N.
A1  - Eckelmann, Baerbel
A1  - Simuyemba, Moses C.
A1  - Msiska, Temwa
A1  - Declich, Giovanna
A1  - Edmunds, Laurel D.
A1  - Kiparoglou, Vasiliki
A1  - Buchan, Alison M. J.
A1  - Williamson, Catherine
A1  - Lord, Graham M.
A1  - Channon, Keith M.
A1  - Surender, Rebecca
A1  - Buchan, Alastair M.
T1  - A global call for action to include gender in research impact assessment
T2  - Health research policy and systems
N2  - Global investment in biomedical research has grown significantly over the last decades, reaching approximately a quarter of a trillion US dollars in 2010. However, not all of this investment is distributed evenly by gender. It follows, arguably, that scarce research resources may not be optimally invested (by either not supporting the best science or by failing to investigate topics that benefit women and men equitably). Women across the world tend to be significantly underrepresented in research both as researchers and research participants, receive less research funding, and appear less frequently than men as authors on research publications. There is also some evidence that women are relatively disadvantaged as the beneficiaries of research, in terms of its health, societal and economic impacts. Historical gender biases may have created a path dependency that means that the research system and the impacts of research are biased towards male researchers and male beneficiaries, making it inherently difficult (though not impossible) to eliminate gender bias. In this commentary, we – a group of scholars and practitioners from Africa, America, Asia and Europe – argue that gender-sensitive research impact assessment could become a force for good in moving science policy and practice towards gender equity. Research impact assessment is the multidisciplinary field of scientific inquiry that examines the research process to maximise scientific, societal and economic returns on investment in research. It encompasses many theoretical and methodological approaches that can be used to investigate gender bias and recommend actions for change to maximise research impact. We offer a set of recommendations to research funders, research institutions and research evaluators who conduct impact assessment on how to include and strengthen analysis of gender equity in research impact assessment and issue a global call for action.
KW  - Research impact assessment
KW  - Gender
KW  - Path dependency
KW  - Health research
KW  - Science policy
KW  - Athena SWAN
KW  - Call for action
Y1  - 2016
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/43169
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-431695
SN  - 1478-4505
N1  - © The Author(s). 2016. Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
VL  - 14
IS  - Art. 50
SP  - 1
EP  - 12
PB  - BioMed Central
CY  - London
ER  -